Drugs / AMP-110
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02277574 | Jun 2014 → Jan 2015 | rheumatoid arthritis | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT01878123 | Apr 2013 → Jul 2014 | rheumatoid arthritis | MedImmune LLC | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-01-08 | Daiichi Sankyo | Daiichi Sankyo and Amplimmune Announce Strategic Alliance to Develop AMP-110 Therapy for Autoimmune Disease daiichisankyo.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMP-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01878123 ↗ |
| Route | Intravenous | “Single intravenous infusion on Day 0” NCT01878123 ↗ |